279 related articles for article (PubMed ID: 7706466)
1. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.
Minotti G; Mancuso C; Frustaci A; Mordente A; Santini SA; Calafiore AM; Liberi G; Gentiloni N
J Clin Invest; 1996 Aug; 98(3):650-61. PubMed ID: 8698856
[TBL] [Abstract][Full Text] [Related]
5. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
6. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
8. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium.
Minotti G; Recalcati S; Mordente A; Liberi G; Calafiore AM; Mancuso C; Preziosi P; Cairo G
FASEB J; 1998 May; 12(7):541-52. PubMed ID: 9576481
[TBL] [Abstract][Full Text] [Related]
9. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; SnabiliƩ AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
10. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
11. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
12. Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol.
Silvestrini A; Meucci E; Vitali A; Giardina B; Mordente A
Chem Res Toxicol; 2006 Nov; 19(11):1518-24. PubMed ID: 17112240
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
14. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
Kwok JC; Richardson DR
Mol Pharmacol; 2003 Apr; 63(4):849-61. PubMed ID: 12644586
[TBL] [Abstract][Full Text] [Related]
15. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
16. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G
Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
Licata S; Saponiero A; Mordente A; Minotti G
Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
[TBL] [Abstract][Full Text] [Related]
19. Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow JH
Cancer Res; 1983 Feb; 43(2):460-72. PubMed ID: 6293697
[TBL] [Abstract][Full Text] [Related]
20. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity.
Kwok JC; Richardson DR
Mol Pharmacol; 2002 Oct; 62(4):888-900. PubMed ID: 12237336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]